Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.
Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models
Schreiner MediPharm notes the Smart Blister Card, which extends standard multi-dose blister packs by a digital adherence monitoring tool enabling tracking of medication intake in real time, received the top honor in the “Innovation & Electronic Printing – Electronic Devices” category.
"We are excited to introduce the Mix-n-Stain™ CF® Dye IgM Antibody Labeling Kits to the scientific community," says Dr. Lori Roberts, Director of Bioscience at Biotium. "This technology provides a new and simple solution to the longstanding challenge of IgM conjugation. We believe these kits will provide researchers with more flexibility in panel design for immunofluorescence and flow cytometry."
Liang Schweizer, PhD, Founder, CEO, and Chairperson of HiFiBiO Therapeutics, “This marks a major step toward further understanding the therapeutic activity of HFB200301 and how we can best deliver safe and effective treatment strategies for cancer patients where other therapeutic options have failed.”
Dr. Jeremy Skillington, Chief Executive Officer of Poolbeg, commented: “The validation of the encapsulation process is a key step in the creation of a Phase I clinical trial ready oral vaccine candidate and Poolbeg is proud to lead the EncOVac Consortium. Delivering oral vaccines to the gut has the potential to revolutionise global protection against infectious disease. In contrast to intramuscular vaccines that generate systemic immunity, oral vaccines induce mucosal immunity, which can induce better protection against pathogens at the site of infection.”
AntiBKV has potential to be first- and best-in-class treatment representing the sole option for large and growing number of patients. Interim data expected by the end of 2023; on track to reach patients in 2025.
After identifying common antibodies unique to individuals resilient to Alzheimer's disease, Alchemab identified the target as CD33. By starting with the body's response to disease, as opposed to the target itself, Alchemab's platform inverts the traditional 'target-led' drug discovery process. In effect, the immune system is used as a search function to identify the most important disease modifying targets.
This proposed change in Valneva’s governance structure will be submitted to the vote of the Company’s shareholders at an Extraordinary General Meeting later this year.
The new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology.
Dr Joanne Mason, Chief Scientific Officer at Yourgene Health, said: “The results of Yourgene’s study with Tommy’s and St Mary’s Hospital greatly improve the feasibility of EDTA tube usage in NIPT, particularly in situations where delayed transport of samples between collection site and analysis locations may occur.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
